News | August 22, 2012

Improved Radiation Technique Offers Treatment for In-stent Restenosis

Radiation can improve outcomes in peripheral stenting


August 22, 2012 — Placement of an endovascular stent has become a common procedure for successfully reopening blocked arteries. Even so, the treated vessel may once again narrow (restenosis), restricting blood flow. In the femoral and popliteal arteries in the leg, the use of nitinol stents magnifies this problem, and about 20 to 40 percent of these stent patients experience restenosis two years after angioplasty. Now, an improved radiation technique may provide a safe and effective solution.

Implantation of the nitinol stent has improved angioplasty outcomes for occlusion of the femoropopliteal arteries, increasing the use of this minimally invasive alternative to surgery. However, stents also exhibit a high rate of in-stent stenosis — new narrowing within the stent due to the vessel’s exaggerated wound healing response. Endovascular brachytherapy is one option for treating this condition.

In some vessels, such as the coronary arteries, radiation localized to the treatment area has been able to prevent recurrent restenosis. Unlike coronary stents, however, femoropopliteal stents have not shown improved response to radiation in the past; results were similar to those after performing angioplasty alone.

The authors of an article in the current issue of the Journal of Endovascular Therapy evaluated the effectiveness of endovascular brachytherapy using liquid beta-emitting rhenium-188 delivered in an angioplasty balloon, an improvement over earlier delivery methods. The balloon provides more accurate dose control than previous catheter techniques. In the clinical setting, the use of beta radiation also offers logistical advantages over the gamma radiation used in previous trials.

Ninety patients underwent angioplasty and endovascular brachytherapy for long-segment in-stent stenosis in the femoropopliteal segment. The treated stents were open in 95 percent of the cases at six months after brachytherapy and in 80 percent at one year. Only nine patients experienced in-stent stenosis and 10 had reocclusion of the treated segment of the artery. At 12 months, 62 percent of the patients showed clinical improvement.

For more information: http://jevt.org/toc/enth/19/4


Related Content

News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
Subscribe Now